Lenalidomide · Regulatory label update

FDA supplemental approval: Lenalidomide (REMS)

U.S. Food and Drug Administration · April 27, 2026

Regulatory Update Why this matters to you Expert discussion

An action by a regulator. Authoritative on labelling and availability.

AI Summary

The FDA approved a supplemental REMS (Risk Evaluation and Mitigation Strategy) for lenalidomide oral capsules in four strengths (2.5 mg, 10 mg, 20 mg, 25 mg) on 27 April 2026. This is a regulatory safety management action and does not contain clinical trial data, efficacy results, or comparative benefit information.

What was studied

Regulatory label update. United States.

Key findings

REMS supplement approved for lenalidomide oral capsules in strengths 2.5 mg, 10 mg, 20 mg, and 25 mg

Safety

No information on the clinical indication, patient population, or safety rationale for the REMS is provided.

Who this may help

The source did not state who this applies to in practice.

Plain-language summary

FDA supplemental approval of a Risk Evaluation and Mitigation Strategy (REMS) for lenalidomide; this is a regulatory action, not a clinical trial, and does not report efficacy or comparative outcomes.

Study design

As stated by the source record.

SettingUnited States

Reported figures

Quoted from the source exactly as published.

Approval date2026-04-27

Caveats

This record does not contain clinical trial results, efficacy data, or comparative outcomes.
The specific content and requirements of the approved REMS are not detailed in this record.
No information on the clinical indication, patient population, or safety rationale for the REMS is provided.
Approval of a REMS supplement is a regulatory action to manage known risks; it does not imply new clinical evidence.

Evidence assessment

Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.

Study design

insufficient

Regulatory action record; no clinical study design present.

Directness

insufficient

No clinical endpoints or trial data reported in this approval record.

Consistency

insufficient

Single regulatory action; no comparative or replicated data.

Risk of bias

insufficient

Regulatory approval does not report study methodology or bias assessment.

Sample adequacy

insufficient

No patient population or sample size described in approval record.

Source abstract

Drugs@FDA record for application ANDA217281. This is a regulatory action record, not a clinical study. Brand name: LENALIDOMIDE. Active ingredient: LENALIDOMIDE. Sponsor: NOVUGEN. Submission type: SUPPL (supplement). Submission class: REMS. Approval status date: 2026-04-27. Products: LENALIDOMIDE, CAPSULE, ORAL, LENALIDOMIDE 20MG; LENALIDOMIDE, CAPSULE, ORAL, LENALIDOMIDE 10MG; LENALIDOMIDE, CAPSULE, ORAL, LENALIDOMIDE 2.5MG; LENALIDOMIDE, CAPSULE, ORAL, LENALIDOMIDE 25MG.

Follow from this

Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.

NovugenLenalidomide